This study links rare genetic variants to type 2 diabetes risk, emphasizing their role in monogenic diabetes and potential ...

A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...

For patients with diabetes, a systolic target of 120 mm Hg led to a significant reduction in CV events in BPROADS, mirroring ...

Mean achieved blood pressure in the two groups was 120.6 mm Hg in the intensive-treatment group and 132.1 mm Hg in the ...

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

An advancement in diabetes treatment has been achieved by Professor Hyun-Wook Kang and his team from the Department of ...

New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat ...

World Day is observed globally on November 14 and the 2024-2026 theme “Diabetes and wellbeing” resonates greatly with how ...

Diabetes is a leading cause of death in the US and can lead to other issues, such as kidney failure, adult-onset blindness ...

People with chronic kidney disease, type 2 diabetes, or both of these conditions may have a higher cardiovascular disease ...